Meibomian Gland Dysfunction Pipeline Insight
DelveInsight’s, “ Meibomian Gland Dysfunction – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meibomian gland dysfunction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Meibomian Gland Dysfunction Understanding
Meibomian Gland Dysfunction: Overview
The meibomian gland is a type of sebaceous gland with tubulo-acinar structure and holocrine function, located in the superior and inferior tarsal plates. Meibomian glands secrete meibum, a compound made up of polar lipids (phospholipids) and nonpolar lipids (cholesterol, wax esters, cholesterol esters).
Meibum is delivered to the ocular surface where it coats the aqueous layer and provides tear film stability and protects against microbial agents and organic matter. Meibomian gland dysfunction (MGD) is a term used to describe a group of disorders, both congenital and acquired, linked by functional abnormalities of the meibomian glands. MGD can lead to altered tear film composition, ocular surface disease, ocular and eyelid discomfort, and evaporative dry eye.
The symptoms of Meibomian Gland Dysfunction include:
- Terminal duct obstruction
- Changes in the glandular secretion
- Eyelid margin foaminess
- Changes in orifice position with respect to the muco-cutaneous junction
The clinical diagnosis of MGD is often made using a combination of subjective symptoms and clinical signs. If asymptomatic, the diagnosis of MGD is only detectable by the presence of clinical signs. The most common clinically observable signs of MGD include MG dropout, altered MG excretions, and changes to the lid morphology with plugging or pouting of the MG orifice being the most pathognomonic sign of MGD. A simple, inexpensive technique to evaluate for MG dropout (partial or complete loss of MGs includes meibography by transillumination of an everted lid at the slit lamp. Infrared meibography has enhanced visualization of the MG, and there are now several commercially available meibographers for clinical use.
Tetracyclines are bacteriostatic antibiotics used in the treatment of MGD primarily for their antiinflammatory properties rather than their antibiotic effects.
Azithromycin is a macrolide antibiotic that is used off-label to treat MGD. Macrolides provide predominantly Gram-positive coverage, inhibiting bacterial protein synthesis by binding to the 23S rRNA molecule of the 50S ribosome subunit. Azithromycin has been found to not only reduce the growth of lid bacteria, but also suppress bacterial lipases and conjunctival inflammation. Cyclosporine A, a calcineurin inhibitor available as a topical 0.05% emulsion (Restasis®, Allergan Inc., Irvine, CA, USA), was the first FDA-approved treatment for dry eye disease. Topical Lifitegrast ophthalmic solution 5.0% (Xiidra®, Shire, and Lexington, MA, USA) is the second and most recent drug approved by the FDA for management of dry eye disease. Essential fatty acids (EFAs) have been found to have anti-inflammatory effects, and oral supplementation with omega-3 fatty acids has been found to be associated with a change in the fatty acid saturation content in meibum.
Meibomian Gland Dysfunction Emerging Drugs Chapters
This segment of the Meibomian Gland Dysfunction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Meibomian Gland Dysfunction Emerging Drugs
NOV03 is a drug that acts as lipid modulators. It is currently in Phase III and is being developed by Bausch & Lomb. The trial got initiated in October 2020 and is expected to get completed by September 2021 with estimated 560 enrolled participants.
- AZR-MD-001: Azura Ophthalmics
AZR-MD-001 is a Phase II/III drug and is being developed by Azura Ophthalmics. The trial got initiated in July 2020 and was to get completed by November 2020 with estimated 30 enrolled participants.
Further product details are provided in the report……..
Meibomian Gland Dysfunction: Therapeutic Assessment
This segment of the report provides insights about the different Meibomian Gland Dysfunction drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Meibomian Gland Dysfunction
There are approx. 10+ key companies which are developing the therapies for Meibomian Gland Dysfunction. The companies which have their Meibomian Gland Dysfunction drug candidates in the most advanced stage, i.e. phase III include, Bausch & Lomb.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Meibomian Gland Dysfunction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Meibomian Gland Dysfunction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Meibomian Gland Dysfunction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Meibomian Gland Dysfunction drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Meibomian Gland Dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve Meibomian Gland Dysfunction.
- In September 2020, Bausch Health announced to acquire all ophthalmology assets of Allegro Ophthalmics.
Meibomian Gland Dysfunction Report Insights
- Meibomian Gland Dysfunction Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Meibomian Gland Dysfunction Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Meibomian Gland Dysfunction drugs?
- How many Meibomian Gland Dysfunction drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Meibomian Gland Dysfunction?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Meibomian Gland Dysfunction therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Meibomian Gland Dysfunction and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bausch & Lomb
- Azura Ophthalmics
- Hovione Scientia